Medivir AB Announces That New Simeprevir Data Will be Presented at the American Association for Study of Liver Diseases Meeting
Published: Nov 04, 2013
Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that new data will be presented on the investigational protease inhibitor simeprevir (TMC435) in treatment-naïve genotype 1 chronic hepatitis C patients and in treatment -experienced patients with compensated liver disease. These data will be presented at the ongoing Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place during November 1 to 5 in Washington, D.C.
Help employers find you! Check out all the jobs and post your resume.